A Phase II Single-arm Study of the Efficacy and Safety of Oral Rigosertib in Patients with Myelofibrosis (MF), Post Myeloproliferative Neoplasm (MPN) and Anemia
You are being asked to take part in this study because you have myelofibrosis (MF), post myeloproliferative neoplasm (MPN), and anemia (a low number of red blood cells). The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. The safety of this drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 08/16/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: